As a consequence of Brexit, the European Medicines Agency (EMA) will leave London and establish its activities elsewhere within the EU. It is believed that this will happen before the end of March 2019 when the process for the UK to leave the EU is concluded. The Swedish government wants EMA to be relocated to Hagastaden and Stockholm Science City assists the Government Offices of Sweden on the candidature.
Picture: Reflex Arkitekter
As a consequence of Brexit, the European Medicines Agency (EMA) will leave London and establish its activities elsewhere within the EU. It is believed that this will happen before the end of March 2019 when the process for the UK to leave the EU is concluded. EMA is one the largest EU bodies with about 900 employees and is responsible for scientific evaluation and supervision of medicines for human and animal use.
The Swedish government wants EMA to be relocated to Hagastaden and offers a seamless transition into an urban and leading life science environment. Stockholm-Uppsala is one of the most innovative regions in the world with strong life science and ICT sectors. Access to competence, ICT-infrastructure and a strong scientific community are key factors for a successful relocation of EMA. Any delay in the scientific evaluation of new medicines may have serious impact on patients in need for new medicines. Therefore, a seamless transition to EMA’s new location is of essence.
SSCi assists the Government offices of Sweden on the candidature and has been involved in the development of the official candidature webpage ematosweden.eu. Since SSCi work for the development of Hagastaden as a geographical hot spot for Life Science and have long time established relations with organisations with interests in Hagastaden, we provide information about science, healthcare and buildings that is relevant for the candidature.
Follow the campaign on social media with #EMAtoSweden and visit the website ematosweden.eu.